“Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy by Prior Treatment in the Phase 3 POETYK PSO-1 Trial”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 6, Nov. 2022, p. s47, https://doi.org/10.25251/skin.6.supp.47.